Business Context and Reporting Period
This Form 8-K Current Report was filed by Proteon Therapeutics, Inc. (PRTO) on August 12, 2019. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Waltham, MA. The report addresses a regulatory notification received from The Nasdaq Stock Market LLC regarding the company's continued listing status.
Key Financial Metrics
The filing references specific financial data from the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2019:
- Stockholders' Equity: $9,477,000
- Nasdaq Minimum Requirement: $10,000,000
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity beyond the stockholders' equity figure.
Material Changes and Listing Status
On August 12, 2019, the company received notification from Nasdaq that its stockholders' equity of $9,477,000 failed to satisfy the continued listing requirement of Rule 5450(b)(1)(A), which mandates a minimum of $10,000,000. This deficiency represents a material change in the company's compliance status. However, the notification has no immediate effect on the listing, and the common stock continues to trade on the Nasdaq Global Market under the symbol "PRTO."
Outlook, Risks, and Management Commentary
The company has 45 calendar days from the date of the notification to submit a plan to regain compliance. Management anticipates submitting this plan timely. If accepted, Nasdaq may grant an extension of up to 180 calendar days to provide evidence of compliance. If the plan is not accepted or an extension is not granted, the company will consider appropriate actions, including appeals to a Nasdaq Listing Qualifications Panel. The filing explicitly states there can be no assurance that the company will be able to regain compliance with the rule.
Investor Verification Checklist
- Verify the company's submission of a compliance plan to Nasdaq within the 45-day window.
- Monitor the acceptance status of the compliance plan and any potential 180-day extension granted by Nasdaq.
- Review the most recent Form 10-Q (ended June 30, 2019) for detailed financial statements regarding the $9,477,000 equity balance.
- Watch for any subsequent filings regarding appeals to the Nasdaq Listing Qualifications Panel if the initial plan is rejected.